Skip to main content
Elekta logo

Elekta — Investor Relations & Filings

Ticker · EKTA ISIN · SE0000163628 LEI · 54930044O54BK617EP80 ST Manufacturing
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2013-05-10 Regulatory Filings
Country SE Sweden
Listing ST EKTA

About Elekta

https://www.elekta.com/

Elekta is a company specializing in precision radiation medicine. It develops and provides clinical solutions, including equipment and software, for treating cancer and brain disorders. The company's portfolio features linear accelerators, the Elekta Unity MR-Linac system, Leksell Gamma Knife for stereotactic radiosurgery, and comprehensive brachytherapy solutions. Elekta also offers oncology informatics software to support treatment planning and clinical workflow. A key focus is advancing adaptive radiotherapy, a personalized approach that utilizes real-time imaging to precisely target tumors and minimize exposure to healthy tissue, aiming to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Canada’s Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
Regulatory Filings Classification · 1% confidence The document is a press release announcing a research partnership between Elekta, Philips, and Sunnybrook Health Sciences Centre regarding MRI-guided radiation therapy. It details the collaboration, the technology involved, and quotes executives. This type of announcement, which is not a formal financial report (like 10-K or IR), dividend notice, or earnings release, typically falls under general corporate news or regulatory disclosure. Since it involves a significant business development (a research consortium expansion) and is structured as a formal press release ending with boilerplate 'About' sections and contact information, it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure that doesn't fit the more specific categories like M&A (TAR) or Capital Change (CAP). The document length (6092 chars) is substantial enough to be the primary document, not just an announcement of a report (RPA).
2013-05-10 English
Number of outstanding shares in Elekta AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document explicitly states the 'Total number of shares' and details the breakdown between A and B shares as of a specific date (April 30, 2013). It also mentions an increase due to the conversion of a convertible bond. This information relates directly to the company's capital structure and share count. This fits best under 'Share Issue/Capital Change' (SHA), which covers changes in capital structure, or potentially 'Capital/Financing Update' (CAP). Since it is a direct notification about the current outstanding share count and a minor change related to financing instruments (convertible bond conversion), SHA is the most precise fit for reporting the resulting share structure change. The document is short and appears to be a direct regulatory disclosure, not an announcement of a larger report.
2013-04-30 English
Antalet utestående aktier i Elekta AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states the total number of outstanding shares ('Antalet utestående aktier') as of a specific date (April 30, 2013). It details the breakdown between A-shares and B-shares and mentions an increase due to the conversion of convertible debt. This information directly relates to the company's capital structure and share count. This fits best under 'Share Issue/Capital Change' (SHA), as it is a notification regarding the current share count and a recent change affecting it (conversion). It is not a general financing announcement (CAP) but a specific update on the share base.
2013-04-30 Swedish
Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy Adds The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Regulatory Filings Classification · 1% confidence The document is a press release announcing that The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital has joined a research consortium with Elekta and Philips to advance MRI-Guided Radiation Therapy technology. It details the collaboration, the technology's benefits, and includes quotes from executives. The text concludes with boilerplate information about the companies and a statement regarding regulatory disclosure ('The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act.'). This structure is characteristic of a general corporate announcement or press release regarding strategic developments, not a formal financial filing like a 10-K, IR, or ER. Since it is a general announcement about a strategic partnership/development that doesn't fit the specific categories (like M&A, Capital Change, or Director Dealing), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings).
2013-04-20 English
Elektas och Philips forskningskonsortium för MRI-styrd strålbehandling utökas med Nederländska Cancerinstitutet vid Antoni van Leeuwenhoek-sjukhuset
Regulatory Filings Classification · 1% confidence The document is a press release dated April 20th, announcing that the Dutch Cancer Institute (NKI-AVL) is joining a research consortium with Elekta and Philips to develop MRI-guided radiation therapy. It details the collaboration, the technology involved, and includes quotes from executives. The text concludes with contact information and boilerplate 'About Us' sections for the involved companies. Crucially, it contains a statement indicating that the information is being made public according to financial instrument laws and specifies the release time ('Informationen lämnades för offentliggörande den 20 april 2013 kl. 08.00 CET'). This structure strongly suggests a general regulatory announcement or press release intended for immediate public disclosure, rather than a comprehensive financial report (like 10-K or IR) or a specific corporate action filing (like DIV or CAP). Since it is a general announcement that doesn't fit the highly specific categories (like DIRS, DVA, or ER), the most appropriate fallback category is Regulatory Filings (RNS). The document length (5863 chars) is substantial enough that it is not just a brief notification of a report being available (RPA), but a substantive announcement itself.
2013-04-20 Swedish
MD Anderson Cancer Center i Houston förvärvar två Versa HD från Elekta
Regulatory Filings Classification · 1% confidence The document is a press release written in Swedish announcing that MD Anderson Cancer Center has acquired two Versa HD systems from Elekta. It details the technology (Versa HD, Agility collimator) and mentions FDA 510(k) clearance. Crucially, the final section states: "Informationen är sådan som Elekta AB (publ) ska offentliggöra enligt lagen om handel med finansiella instrument och/eller lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 18 april 2013 kl. 07.30 CET." This structure—a brief announcement of news followed by a mandatory disclosure statement regarding financial instrument laws—is characteristic of a regulatory filing intended for immediate public dissemination, often categorized as a general regulatory announcement or press release that doesn't fit a specific financial report type (like 10-K, ER, or IR). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, time-sensitive regulatory announcement that is not a standard financial report or management change notice.
2013-04-18 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.